S-1与卡培他滨分别联合奥沙利铂治疗晚期结直肠癌的临床疗效研究

A Clinical Study on the Efficacy of S-1 plus Oxaliplatin versus Capecitabine plus Oxaliplatin for Patients with Advanced Colorectal Cancer

目的分析和比较S-1与卡培他滨分别联合奥沙利铂治疗晚期结直肠癌的近期疗效和安全性。方法将57例晚期结直肠癌患者随机分为SOX组和Cape OX组,SOX组患者采用S-1联合奥沙利铂治疗,Cape OX组患者采用卡培他滨联合奥沙利铂治疗。观察和比较两组患者的近期疗效和不良反应发生情况。结果 SOX组的客观有效率(ORR)为48.1%,与Cape OX组(46.7%)比较,差异无统计学意义(P>0.05)。两组患者疾病控制率(DCR)比较,差异无统计学意义(P>0.05)。两组骨髓抑制、胃肠道反应、口腔黏膜炎、肾损害和神经毒性的发生率比较,差异无统计学意义(P>0.05),SOX组肝损害发生率高于Cape OX组(P<0.05),Cape OX组手足综合征发生率高于SOX组(P<0.05)。SOX组患者1年生存率为55.6%,Cape OX组为56.7%,两组比较差异无统计学意义。结论 S-1联合奥沙利铂和卡培他滨联合奥沙利铂治疗晚期结直肠癌的疗效相当,副反应有所区别,临床上可根据不同患者选择合理的治疗方案。

Objective To determine and compare the efficacy and tolerance of S-1 plus oxaliplatin and capecitabine plus oxaliplatin for advanced colorectal cancer. Methods Fifty-seven cases of patients with advanced colorectal cancer were randomly divided into SOX group and CapeOX group. The SOX group were treated with S-1 plus oxaliplatin regimen, while the CapeOX group were treated with capecitabine plus oxaliplatin regimen. Efficacy of chemotherapy and the occurrence of side effects of the two groups were observed and compared. Results Total efficiency of the SOX group was 48.1%, and it was 46.7% in the CapeOX group, there was no statistical difference between the two groups （P 〉 0.05）. After chemotherapy, the disease control rate （DCR） also showed no statistical difference between the two groups （P 〉 0.05）. There were also no significant differences in the incidence of adverse reactions such as bone marrow suppression, gastrointestinal reactions, oral mucosal lesions, kidney damage and neurological toxicity between the two groups （P〉0.05）. However, the incidence of liver injury of the SOX group was significantly higher than that of the CapeOX group, with statistical difference （P 〈 0.05）. Yet the incidence of hand-foot syndrome of SOX group was lower than that of the CapeOX group, and the difference was statistically significant （P 〈 0.05）. The 1-year sur- vival rate was 55.6% in the SOX group, and was 56.7% in the CapeOX group. There was no statistically significant difference in the 1-year survival rate between the two groups （P〉 0.05）. Conclusion S-1 combined with oxaliplatin program had equivalent efficacy to capecitabine combined with oxaliplatin program for advanced colorectal cancer patients. But they had each advatanges and disadvantages in adverse ef- fect. So the suitable program should be selected according to the individual conditions of each patient.